Shares of Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) were down 3.9% on Friday . The stock traded as low as $0.80 and last traded at $0.80. Approximately 12,431 shares traded hands during trading, an increase of 148% from the average daily volume of 5,004 shares. The stock had previously closed at $0.83.
Kiromic BioPharma Stock Performance
The business has a 50-day moving average price of $0.94 and a 200-day moving average price of $1.35.
Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.65) earnings per share for the quarter.
About Kiromic BioPharma
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Featured Articles
- Five stocks we like better than Kiromic BioPharma
- Energy and Oil Stocks Explained
- MP Materials: Rare Earth Elements Powering the EV Boom
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- What Does Downgrade Mean in Investing?
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
